60 Degrees Pharmaceuticals, Inc. (SXTP): EBITDA
-$7.72M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$7.72M | n/m | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | -$9.70M | n/m | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | -$5.13M | n/a | 2025-03-27, From 2023-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | -$7.72M | n/m |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | -$47.81M | n/m |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | -$11.92M | n/m |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | -$28.87M | n/m |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | -$7.05M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$15.79M | n/m |
| Rallybio Corp (RLYB) | 2025-12-31 | -$32.97M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | -$22.49M | n/m |
| Onconetix, Inc. (ONCO) | 2025-12-31 | -$17.84M | n/m |
Compare SXTP, STTK, DARE, RFL side by side · Screen every company in Pharmaceutical Preparations ↗